Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving Infliximab: A case report

被引：27

作者：

Justice E.A. ^{[1
]}

Khan S.Y. ^{[1
]}

Logan S. ^{[1
]}

Jobanputra P. ^{[1
]}

机构：

[1] Rheumatology Department, Selly Oak Hospital, University Hospital Birmingham NHS Trust, Birmingham B29 6JD, Raddlebarn Road

来源：

Journal of Medical Case Reports | / 2卷 / 1期

关键词：

Psoriasis; Infliximab; Etanercept; Adalimumab; Acyclovir;

D O I：

10.1186/1752-1947-2-282

中图分类号：

学科分类号：

摘要：

Introduction: We present the case of a 49-year-old woman with a seronegative rheumatoid arthritis who developed pustular psoriasis whilst on etanercept and subsequently developed disseminated herpes simplex on infliximab. Case presentation: Our patient presented with an inflammatory arthritis which failed to respond to both methotrexate and leflunomide, and sulphasalazine treatment led to side effects. She was started on etanercept but after 8 months of treatment developed scaly pustular lesions on her palms and soles typical of pustular psoriasis. Following the discontinuation of etanercept, our patient required high doses of oral prednisolone to control her inflammatory arthritis. A second biologic agent, infliximab, was introduced in addition to low-dose methotrexate and 15 mg of oral prednisolone. However, after just 3 infusions of infliximab, she was admitted to hospital with a fever, widespread itchy vesicular rash and worsening inflammatory arthritis. Fluid from skin vesicles examined by polymerase chain reaction showed Herpes Simplex Virus type 1. Blood cultures were negative and her chest X-ray was normal. Her infliximab was discontinued and she was started on acyclovir, 800 mg five times daily for 2 weeks. She made a good recovery with improvement in her skin within 48 hours. She continued for 2 months on a prophylactic dose of 400 mg bd. Her rheumatoid arthritis became increasingly active and a decision was made to introduce adalimumab alongside acyclovir. Acyclovir prophylaxis has been continued but the dose tapered so that she is taking only 200 mg of acyclovir on alternate days. There has been no recurrence of Herpes Simplex Virus lesions despite increasing adalimumab to 40 mg weekly 3 months after starting treatment. Conclusion: We believe this to be the first reported case of widespread cutaneous Herpes Simplex Virus type 1 infection following treatment with infliximab. We discuss the clinical manifestations of Herpes Simplex Virus infections with particular emphasis on the immunosuppressed patient and the use of prophylactic acyclovir. Pustular psoriasis is now a well recognised but uncommon side effect of antitumour necrosis factor therapy and can lead to cessation of therapy, as in our patient's case. © 2008 Ann Justice et al; licensee BioMed Central Ltd.

引用

共 15 条

[1]

Xu F., Sternberg M.R., Kottiri B.J., McQuillan G.M., Lee F.K., Nahmias A.J., Berman S.M., Markowitz L.E., Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States, JAMA, 296, 8, pp. 964-973, (2006)

[2]

Oxman M.N., Herpes simplex viruses and human herpes virus 6, Infectious Disease, pp. 1667-1700, (1992)

[3]

Sharma S., Mosunjac M., Herpes simplex hepatitis in adults: A search for muco-cutaneous clues, J Clin Gastroenterol, 38, 8, pp. 697-704, (2004)

[4]

Ferrari A., Luppi M., Potenza L., Riva G., Morselli M., Imovilli A., Volzone F., Rossi G., Codeluppi M., Guaraldi G., Torelli G., Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukaemia: Case report and review of literature, Leukemia, 19, 11, pp. 2019-2021, (2005)

[5]

Shimeld C., Easty D.L., Hill T.J., Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: An in vivo study of virus antigen and cytokines, J Virol, 73, 3, pp. 1767-1773, (1999)

[6]

Minagawa H., Hashimoto K., Yanagi Y., Absence of tumour necrosis factor facilitates primary and recurrent herpes simplex virus-1 infections, J Gen Virol, 85, pp. 343-347, (2004)

[7]

Minami M., Kita M., Yan X.Q., Yamamoto T., Iida T., Sekikawa K., Iwakura Y., Imanishi J., Role of IFN-gamma and tumour necrosis factor-alpha in herpes simplex virus type 1 infection, J Interferon Cytokine Res, 22, 2, pp. 671-676, (2002)

[8]

Erlandsson A.C., Bladh L.G., Stierna P., Yucel-Lindberg T., Hammarsten O., Modeer T., Harmenberg J., Wikstrom A.C., Herpes simplex virus type 1 infection and glucocorticoid treatment regulate viral yield, glucocorticoid receptor and NF-kappaB levels, J Endocrinol, 175, pp. 165-176, (2002)

[9]

Wertheim P., Slaterus K.W., Geelen J.L., Noordaa J., Wilmink J.M., Cytomegalo and herpes simplex virus infections in renal transplant recipients, Scand J Urol Nephrol Suppl, 92, pp. 5-8, (1985)

[10]

Lefore S., Anderson P.L., Fletcher C.V., A risk-benefit evaluation of Aciclovir for the treatment and prophylaxis of herpes simplex virus infections, Drug Saf, 23, 2, pp. 113-142, (2000)

← 1 2 →